Literature DB >> 3524664

Labetalol does not alter the placental and fetal blood flow or maternal prostanoids in pre-eclampsia.

P Jouppila, P Kirkinen, A Koivula, O Ylikorkala.   

Abstract

The effect of intravenously administered labetalol (1 mg/kg) on placental and fetal blood flow was studied in 13 pre-eclamptic women. Although the maternal blood pressure decreased, no changes occurred in the blood flows in the intervillous space, the umbilical vein or the fetal descending aorta, nor did the indices of peripheral vascular resistance in the fetal aorta change, but the placental vascular resistance did decrease. Labetalol had no effect on prostacyclin or thromboxane A2 as measured by urinary 6-keto-prostaglandin F1 alpha and serum thromboxane B2 respectively. These findings are clinically relevant since they suggest that labetalol reduces maternal blood pressure without interfering with the placental or fetal blood flow.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3524664     DOI: 10.1111/j.1471-0528.1986.tb07951.x

Source DB:  PubMed          Journal:  Br J Obstet Gynaecol        ISSN: 0306-5456


  7 in total

Review 1.  Comparative risk-benefit assessment of drugs used in the management of hypertension in pregnancy.

Authors:  P M Kyle; C W Redman
Journal:  Drug Saf       Date:  1992 May-Jun       Impact factor: 5.606

2.  Changes in adrenoceptors and monoamine metabolism in neonatal and adult rat brain after postnatal exposure to the antihypertensive labetalol.

Authors:  E B Erdtsieck-Ernste; M G Feenstra; M H Botterblom; J De Barrios; G J Boer
Journal:  Br J Pharmacol       Date:  1992-01       Impact factor: 8.739

3.  Half-life of maternal labetalol in a premature infant.

Authors:  A Haraldsson; W Geven
Journal:  Pharm Weekbl Sci       Date:  1989-12-15

Review 4.  Effects of antihypertensive drugs on the unborn child: what is known, and how should this influence prescribing?

Authors:  S M Khedun; B Maharaj; J Moodley
Journal:  Paediatr Drugs       Date:  2000 Nov-Dec       Impact factor: 3.022

Review 5.  Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease.

Authors:  K L Goa; P Benfield; E M Sorkin
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

Review 6.  Report of the Canadian Hypertension Society Consensus Conference: 3. Pharmacologic treatment of hypertensive disorders in pregnancy.

Authors:  E Rey; J LeLorier; E Burgess; I R Lange; L Leduc
Journal:  CMAJ       Date:  1997-11-01       Impact factor: 8.262

7.  Pre-gestational diabetes: Maternal body mass index and gestational weight gain are associated with augmented umbilical venous flow, fetal liver perfusion, and thus birthweight.

Authors:  Agnethe Lund; Cathrine Ebbing; Svein Rasmussen; Elisabeth Qvigstad; Torvid Kiserud; Jörg Kessler
Journal:  PLoS One       Date:  2021-08-16       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.